# Maintenance of Remission With Budesonide Orodispersible Tablets vs. Placebo in Eosinophilic Esophagitis

> **NCT02493335** · PHASE3 · COMPLETED · sponsor: **Dr. Falk Pharma GmbH** · enrollment: 204 (actual)

## Conditions studied

- Eosinophilic Esophagitis

## Interventions

- **DRUG:** Budesonide 0.5mg orodispersible tablet twice daily
- **DRUG:** Budesonide 1mg orodispersible tablet twice daily
- **DRUG:** Placebo orodispersible tablet twice daily

## Key facts

- **NCT ID:** NCT02493335
- **Lead sponsor:** Dr. Falk Pharma GmbH
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-01-15
- **Primary completion:** 2018-11-28
- **Final completion:** 2020-12-11
- **Target enrollment:** 204 (ACTUAL)
- **Last updated:** 2021-10-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02493335

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02493335, "Maintenance of Remission With Budesonide Orodispersible Tablets vs. Placebo in Eosinophilic Esophagitis". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02493335. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*